Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

Janssen Pharmaceuticals, a subsidiary of the giant manufacturing company, Johnson & Johnson (NYSE:JNJ) has expanded the current partnership with the long-beleaguered Geron Corporation (NASDAQ:GERN). The newly formed partnership is for the worldwide and exclusive rights to the biotech’s oligonucleotide backbone chemistry and the novel amides for ribonucleic acid interference or RNAi. The latter is used in the prevention, treatment, and diagnosis of any disease.

The Janssen Pharmaceuticals and Geron partnership specifically does not include any approach to bone marrow and blood originating cancers, including any product that works primarily via telomerase inhibition. These exclusions, however, have already been covered under a current deal between the two companies which was previously executed on November 2014.

Kritchanut/Shutterstock.com

In addition to this, Janssen has also been given a non-exclusive worldwide license to monomer synthesis technology. Monomers, known to be the building blocks of oligonucleotides, are stated to be used as part of the imetelstat program. Imetelstat is a modified short oligonucleotide. The particular imetelstat program was already licensed previously in a deal made back in 2014.

Aside from an upfront payment amounting to $5 million, Geron is eligible for development and regulatory milestones budget amounting to $75 million. This is in addition to existing low single digit royalties on the net sales of any resulting product marketed worldwide.

The motion to build a partnership with Geron Corporation (NASDAQ:GERN) comes ahead of a Janssen decision on continuing to advance with telomerase inhibitor imetelstat. Janssen is nominated to come up with a decision on whether to go on with the Phase III portion of a Phase II/III trial on the coming second quarter next year. If things go forward, patient enrollment in the Phase III portion is slated for mid-2017.

According to data, the two-armed and planned 200-patient Phase II portion of the imetelstat trial in the medication of intermediate-2 or high-risk myelofibrosis (MF) patients hasn’t been particularly promising. These patients are those who are refractory to or who have relapsed after treatment with a JAK inhibitor.

Follow Geron Corp (NASDAQ:GERN)Follow Geron Corp (NASDAQ:GERN)

Trade (NASDAQ:GERN) Now!

Note: This article is written by Andy Parker and was originally published at Market Exclusive.